JNGHF
Jiangsu Hengrui Pharmaceuticals Co., Ltd.$5.80 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $5.80
Since first trade
−4.9%
from $6.10 · Aug 24
30 days
0.0%
from $5.80
Range since listing
$5.80–6.10
−5% from high · low Sep 16
Avg volume 20D
0
Sep 28 spike 0
Short interest
🔒 Subscribers only
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- X Aug 31 Short interest jumps 870.1% to 3.86M
Signal stack
Where each data set points today.
- TrendDOWNTREND
2% below its 44-day average. New closing low $5.80 on Oct 23.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
May 29, 2026 Clinical trial readout
Results Pending: HRS-9190 (Phase 2) — Completed 14d ago
Trial: Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults Sponso
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
May 29, 2026
Trial readout
Results Pending: HRS-9190 (Phase 2) — Completed 14d ago
Trial: Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults Sponsor: Jiangsu HengRui Medicine Co., Ltd. Phase…
May 28, 2026
Clinical Trial
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Phase 2 · COMPLETED
May 22, 2026
Clinical Trial
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Phase 2 · COMPLETED
May 3, 2026
Trial readout
T-90d Trial Readout: TACE+Camrelizumab+Apatinib mesylate (Phase 3)
Trial: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma Sponsor: Jiangsu…
May 3, 2026
Trial readout
T-90d Trial Readout: Camrelizumab (Phase 3)
Trial: A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk…
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | — | — | — | $33.6B |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short